ABHD12 Gene

ABHD12 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABHD12 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ABHD12</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Alpha/Beta Hydrolase Domain Containing 12</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p11.21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>553155</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000153048</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NWU1</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>613599</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>27.3 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>14</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>2.1 kb</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Product</td>
</tr>
<tr>
<td class="label">2-Arachidonoylglycerol (2-AG)</td>
<td>Arachidonic acid + glycerol</td>
</tr>
<tr>
<td class="label">1-Arachidonoylglycerol (1-AG)</td>
<td>Arachidonic acid + glycerol</td>
</tr>
<tr>
<td class="label">Lysophosphatidylserine</td>
<td>Fatty acid + serine</td>
</tr>
<tr>
<td class="label">Lysophosphatidylethanolamine</td>
<td>Fatty acid + ethanolamine</td>
</tr>
<tr>
<td class="label">Palmitoylethanolamide</td>
<td>Palmitic acid + ethanolamine</td>
</tr>
<tr>
<td class="label"

ABHD12 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ABHD12 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>ABHD12</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Alpha/Beta Hydrolase Domain Containing 12</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>20p11.21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>553155</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000153048</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9NWU1</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>613599</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>27.3 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>14</td>
</tr>
<tr>
<td class="label">mRNA Length</td>
<td>2.1 kb</td>
</tr>
<tr>
<td class="label">Substrate</td>
<td>Product</td>
</tr>
<tr>
<td class="label">2-Arachidonoylglycerol (2-AG)</td>
<td>Arachidonic acid + glycerol</td>
</tr>
<tr>
<td class="label">1-Arachidonoylglycerol (1-AG)</td>
<td>Arachidonic acid + glycerol</td>
</tr>
<tr>
<td class="label">Lysophosphatidylserine</td>
<td>Fatty acid + serine</td>
</tr>
<tr>
<td class="label">Lysophosphatidylethanolamine</td>
<td>Fatty acid + ethanolamine</td>
</tr>
<tr>
<td class="label">Palmitoylethanolamide</td>
<td>Palmitic acid + ethanolamine</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Enzyme Replacement</td>
<td>Recombinant ABHD12 protein delivery</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>AAV-mediated ABHD12 expression</td>
</tr>
<tr>
<td class="label">Substrate Reduction</td>
<td>Inhibiting 2-AG synthesis to prevent accumulation</td>
</tr>
<tr>
<td class="label">Anti-inflammatory</td>
<td>Targeting downstream effects of ABHD12 deficiency</td>
</tr>
<tr>
<td class="label">Small Molecule Activators</td>
<td>Direct ABHD12 activation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>IC50</td>
</tr>
<tr>
<td class="label">Compound A</td>
<td>50 nM</td>
</tr>
<tr>
<td class="label">Compound B</td>
<td>200 nM</td>
</tr>
<tr>
<td class="label">Organophosphate</td>
<td>10 nM</td>
</tr>
<tr>
<td class="label">Variant Type</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Pathogenic LOF</td>
<td>Very rare</td>
</tr>
<tr>
<td class="label">Missense</td>
<td>Rare</td>
</tr>
<tr>
<td class="label">Common SNPs</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">6 edges</a></td>
</tr>
</table>

ABHD12 (Alpha/Beta Hydrolase Domain Containing 12) encodes a brain-enriched serine hydrolase enzyme that plays critical roles in lipid metabolism, endocannabinoid signaling, and neuroimmune function. ABHD12 is highly expressed in the central nervous system, particularly in neurons, microglia, and oligodendrocytes, where it hydrolyzes various lipid substrates including monoacylglycerols (MAGs), phospholipids, and fatty acid derivatives[@blankman2013][@long2012].

ABHD12 was initially characterized due to its association with PHARC syndrome (Polyneuropathy, Hearing loss, Ataxia, Retinitis pigmentosa, and early-onset cataract), a rare autosomal recessive neurodegenerative disorder. However, recent research has revealed that ABHD12 dysfunction also contributes to more common neurodegenerative conditions including Alzheimer's disease (AD) and Parkinson's disease (PD), through effects on neuroinflammation, synaptic function, and lipid homeostasis[@tessitore2010][@ruiz2023].

Gene Overview

Protein Structure and Function

Enzyme Classification

ABHD12 belongs to the α/β-hydrolase family of enzymes, characterized by a conserved catalytic domain featuring:

Substrate Specificity

ABHD12 hydrolyzes a range of lipid substrates:

Expression Pattern

In the brain, ABHD12 exhibits cell-type-specific expression:

• Neurons: High expression in cortical pyramidal neurons, hippocampal CA1 neurons, and cerebellar Purkinje cells
• Microglia: Moderate expression, increased in disease states
• Oligodendrocytes: High expression for myelin lipid metabolism
• Astrocytes: Low to moderate expression

Role in PHARC Syndrome

Clinical Features

Biallelic loss-of-function mutations in ABHD12 cause PHARC syndrome, characterized by:

Pathophysiology

The mechanism of neurodegeneration in PHARC involves:

• Accumulation of ABHD12 substrates (particularly 2-AG) in neural tissues
• Dysregulated endocannabinoid signaling
• Impaired lipid membrane remodeling
• Progressive neuronal dysfunction and loss

Role in Alzheimer's Disease

Neuroinflammation

ABHD12 plays a crucial role in regulating neuroinflammatory responses:

• Microglial Activation: ABHD12 deficiency leads to enhanced microglial activation and pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)[@ruiz2023].
• Inflammasome Regulation: ABHD12 regulates NLRP3 inflammasome activity through lipid mediator metabolism.
• Complement Activation: ABHD12 influences complement system activation in the brain[@parisi2023].

Amyloid-Beta Metabolism

ABHD12 affects Aβ pathology through multiple mechanisms:

Cognitive Function

Mouse models of ABHD12 deficiency exhibit:

• Impaired spatial learning and memory in Morris water maze
• Reduced hippocampal long-term potentiation (LTP)
• Synaptic protein loss and dendritic spine abnormalities[@ferris2023]

Clinical Evidence

Human studies reveal:

• Reduced ABHD12 expression in AD brain tissue, particularly in hippocampus and cortex[@martinez2024]
• ABHD12 promoter variants associated with increased AD risk through epigenetic mechanisms[@singh2024]
• ABHD12 expression correlates with cognitive decline severity

Role in Parkinson's Disease

Emerging evidence links ABHD12 to Parkinson's disease pathogenesis:

• Alpha-Synuclein Aggregation: ABHD12 dysfunction may promote α-synuclein aggregation through altered lipid homeostasis
• Dopaminergic Neuron Vulnerability: ABHD12 deficiency increases susceptibility of dopaminergic neurons to Parkinsonian toxins
• Neuroinflammation: Similar microglial activation patterns as observed in AD

Therapeutic Targeting

Related Pathways

Interacting Proteins

ABHD12 interacts with several key proteins:

• FAAH: Fatty acid amide hydrolase, another endocannabinoid-metabolizing enzyme
• MAGL: Monoacylglycerol lipase, main 2-AG hydrolase in brain
• GPR55: Cannabinoid receptor involved in lipid signaling
• TREM2: Microglial receptor for Aβ phagocytosis
• APOE: Apolipoprotein involved in lipid transport

Research Directions

Key unanswered questions include:

Clinical Perspectives

Diagnostic Approaches

ABHD12 and its lipid substrates have potential as biomarkers:

• 2-AG Levels: Elevated cerebrospinal fluid 2-AG in ABHD12-deficient individuals
• Enzyme Activity: Measuring ABHD12 activity in peripheral blood mononuclear cells
• Genetic Testing: Identifying carriers of pathogenic ABHD12 variants
• Neuroimaging: PET imaging of neuroinflammation in ABHD12-deficient patients

Therapeutic Strategies

Several approaches are being explored:

Biochemical Properties

Enzyme Kinetics

ABHD12 exhibits the following biochemical characteristics:

• Optimal pH: 7.4-8.0, matching physiological conditions in cells
• Temperature Sensitivity: Activity peaks at 37°C
• Substrate Affinity: Low micromolar Km for 2-AG
• Inhibition: Sensitive to organophosphates and serine hydrolase inhibitors

Structure-Function Relationships

Key structural features:

Pharmacological Modulation

Inhibitors

Current ABHD12 inhibitors in development:

Activators

Potential ABHD12 activators:

• Allosteric Modulators: Bind non-active site regions
• Protein-Protein Interaction Disrupters: Block negative regulators
• Expression Enhancers: Increase ABHD12 transcription

Epidemiology and Genetics

Disease Prevalence

• PHARC Syndrome: ~1 in 500,000 to 1 in 1,000,000
• Heterozygote Carriers: Usually asymptomatic
• Founder Effects: Higher prevalence in specific populations

Genetic Variation

Animal Models

PHARC Mouse Models

• ABHD12 Knockout: Recapitulates key features of PHARC including neuropathy and hearing loss
• Conditional Knockouts: Cell-type-specific deletion to understand tissue-specific functions

Behavioral Phenotypes

ABHD12-deficient mice show:

• Impaired spatial learning in Morris water maze
• Reduced hippocampal long-term potentiation
• Enhanced anxiety-like behavior
• Motor coordination deficits

Research Gaps and Future Directions

Key priorities for ABHD12 research:

Mechanism Map

See Also

• [PHARC Syndrome](/diseases/pharc-syndrome) — ABHD12-related disorder
• [Endocannabinoid Signaling](/mechanisms/endocannabinoid-signaling) — 2-AG pathway
• [Lipid Metabolism](/mechanisms/lipid-metabolism) — Brain lipid homeostasis
• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD overview
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD overview
• [Microglia](/entities/microglia) — Brain immune cells
• [Endocannabinoid System](/mechanisms/endocannabinoid-system) — Cannabinoid signaling

Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
• [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression

References